Basmisanil, an Α5-Gabaar Negative Allosteric Modulator, Produces Rapid and Sustained Antidepressant-Like Responses in Male Mice

There is a critical need for safer and better -tolerated alternatives to address the current limitations of antidepressant treatments for major depressive disorder. Recently, drugs targeting the GABA system via alpha 5-containing GABA A receptors (alpha 5-GABA A R) as negative allosteric modulators (alpha 5-NAMs) have shown promise in alleviating stress -related behaviors in preclinical studies, suggesting that alpha 5-NAMs may have translational relevance as novel antidepressant medications. Here, we evaluated the efficacy of Basmisanil, an alpha 5-NAM that has been evaluated in Phase 2 clinical studies as a cognitive enhancer, in a battery of behavioral tests relevant to coping strategies, motivation, and aversion in male mice, along with plasma and brain pharmacokinetic measurements. Our findings reveal that Basmisanil induces dose -dependent rapid antidepressant -like responses in the forced swim test and sucrose splash test without promoting locomotor stimulating effects. Furthermore, Basmisanil elicits sustained behavioral responses in the female urine sniffing test and sucrose splash test, observed 24 h and 48 h post -treatment, respectively. Bioanalysis of plasma and brain samples confirms effective blood-brain barrier penetration by Basmisanil and extrapolation to previously published data suggest that effects were observed at doses (10 and 30 mg/kg i.p.) corresponding to relatively modest levels of alpha 5-GABA A R occupancy (40-65 %). These results suggest that Basmisanil exhibits a combination of rapid and sustained antidepressant -like effects highlighting the potential of alpha 5-NAMs as a novel therapeutic strategy for depression.